Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Derinat for Acute Respiratory Infections in Children
NCT04149431Phase 3Unknown
- Sponsor
- PharmPak
- Start
- Dec 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute upper respiratory tract infection (URI) comparing Derinat with Placebo (2 arms). Primary endpoint: Superiority of Derinat at 30 days. Status: unknown.
02
Drugs
sodium desoxyribonucleate
03
Conditions
acute upper respiratory tract infection (URI)
Beyond the preview
Go deeper on NCT04149431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149431.